Tema Etfs LLC Has $1.24 Million Stock Holdings in Janux Therapeutics, Inc. $JANX

Key Points

• Tema Etfs LLC significantly increased its stake in Janux Therapeutics by 779.5%, owning approximately 0.08% of the company worth $1.24 million after acquiring an additional 40,714 shares.
• Several large investors, including Bank of America Corp DE and Wellington Management Group LLP, also boosted their stakes in Janux Therapeutics substantially during the fourth quarter, indicating strong institutional interest.
• Janux Therapeutics reported an EPS of ($0.55) for the last quarter, missing expectations, while analysts have an average rating of "Buy" with a consensus target price of $86.90.

Tema Etfs LLC increased its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 779.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 45,937 shares of the company's stock after purchasing an additional 40,714 shares during the quarter. Tema Etfs LLC owned approximately 0.08% of Janux Therapeutics worth $1,240,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of JANX. Wells Fargo & Company MN raised its holdings in shares of Janux Therapeutics by 52.9% in the 4th quarter. Wells Fargo & Company MN now owns 13,251 shares of the company's stock valued at $709,000 after purchasing an additional 4,585 shares during the period. First Trust Advisors LP bought a new position in Janux Therapeutics in the 4th quarter valued at about $6,856,000. MetLife Investment Management LLC raised its holdings in Janux Therapeutics by 5.8% in the 4th quarter. MetLife Investment Management LLC now owns 17,298 shares of the company's stock valued at $926,000 after acquiring an additional 949 shares during the period. Tower Research Capital LLC TRC raised its holdings in Janux Therapeutics by 878.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock valued at $205,000 after acquiring an additional 3,436 shares during the period. Finally, Aquatic Capital Management LLC bought a new position in Janux Therapeutics in the 4th quarter valued at about $330,000. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Stock Down 1.4%

Shares of JANX traded down $0.33 during mid-day trading on Monday, hitting $22.72. 456,346 shares of the company's stock were exchanged, compared to its average volume of 807,162. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -12.62 and a beta of 2.84. The stock's 50-day simple moving average is $24.52 and its 200-day simple moving average is $27.08. Janux Therapeutics, Inc. has a 52 week low of $21.97 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.07). Analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

JANX has been the topic of several research analyst reports. Piper Sandler initiated coverage on shares of Janux Therapeutics in a report on Monday, August 18th. They issued an "overweight" rating and a $42.00 price target on the stock. Raymond James Financial initiated coverage on shares of Janux Therapeutics in a report on Friday, July 11th. They issued an "outperform" rating and a $65.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $86.90.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.